Ionis-AZ readout sets up challenge for Alnylam in initial amyloidosis indication

Days after Alnylam gained approval of Amvuttra in an amyloidosis indication, Ionis and partner AstraZeneca said a pivotal readout for eplontersen, their potential blockbuster competitor, will support a regulatory submission.

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and AstraZeneca plc (LSE:AZN; NASDAQ:AZN) said eplontersen, an antisense oligonucleotide, met two co-primary endpoints in the Phase III NEURO-TTRansform trial to treat polyneuropathy associated with hereditary TTR-mediated amyloidosis (hATTR)...